Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the viability of aldesleukin as a routine treatment for people who have had a heart attack.

The National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre and the NIHR Cambridge Clinical Research Facility are supporting research into the benefits of low doses of aldesleukin for people who have experienced a heart attack, to reduce inflammation in the arteries after the initial heart attack.